Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update
24 Octobre 2023 - 1:30PM
Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the
“Company”), a clinical-stage biopharmaceutical company leveraging
its extensive virology expertise to develop novel therapeutics that
target specific viral diseases, today announced that it has
scheduled its third quarter 2023 financial results and corporate
update for Tuesday, November 7, 2023. The schedule for the press
release and conference call/webcast are as follows:
• |
Q3/2023 Press Release: |
Tuesday, November 7, 2023 at 7:30 a.m. ET |
• |
Q3/2023 Conference Call/Webcast: |
Tuesday, November 7, 2023 at 8:45 a.m. ET |
|
|
|
To dial-in for the conference call by phone,
please register using the following link: Registration Link. A live
webcast of the conference call can be accessed through the
Investors section of Arbutus' website at www.arbutusbio.com.
An archived webcast will be available on the
Arbutus website after the event.
About Arbutus
Arbutus Biopharma Corporation (Nasdaq: ABUS) is
a clinical-stage biopharmaceutical company leveraging its extensive
virology expertise to identify and develop novel therapeutics with
distinct mechanisms of action, which can be combined to provide a
functional cure for patients with chronic hepatitis B virus (cHBV).
We believe the key to success in developing a functional cure
involves suppressing HBV DNA, reducing surface antigen, and
boosting HBV-specific immune responses. Our pipeline of internally
developed, proprietary compounds includes an RNAi therapeutic,
imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran
is the only RNAi that has generated meaningful clinical data
demonstrating an impact on both surface antigen reduction and
reawakening of the HBV-specific immune response. Imdusiran is
currently in two Phase 2a combination clinical trials. AB-101 is
currently being evaluated in a Phase 1a/1b clinical trial. We are
also exploring oncology applications for our internal PD-L1
portfolio. For more information, visit www.arbutusbio.com.
Contact Information
Investors and Media
Lisa M. CaperelliVice President, Investor RelationsPhone:
215-206-1822Email: lcaperelli@arbutusbio.com
Arbutus Biopharma (NASDAQ:ABUS)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Arbutus Biopharma (NASDAQ:ABUS)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024